Why oral micronized progesterone causes mood changes, how long they last, management strategies, and alternative progestogens that may spare mood. Evidence-based guide with clinical trials and guidelines.
Evidence-based dietary strategies to reduce mood side effects from oral micronized progesterone (Prometrium), including specific nutrients, meal timing, and foods that modulate allopregnanolone activity.
A clinical severity grading rubric for mood changes caused by oral micronized progesterone (Prometrium), including mechanism, management strategies, and when to contact your prescriber.
When mood changes from oral micronized progesterone persist beyond the expected adjustment period, here is what to evaluate, when to switch formulations, and how to work with your prescriber.
Learn when mood changes from oral micronized progesterone require medical attention, how to manage them, and why this hormone affects your brain chemistry.
Prometrium's label directs one bedtime dose because of drowsiness. Dizziness was 15% vs 9% with 200 mg and 24% vs 4% with 400 mg, against placebo.
Learn why oral micronized progesterone causes sedation through its allopregnanolone metabolite, how to manage drowsiness, and when sedation signals a need for medical attention.
A clinical severity grading rubric for diarrhea caused by Ozempic (semaglutide 0.5 to 2 mg), including CTCAE grades, management by tier, and when to contact your prescriber.
Evidence-based guide to semaglutide-induced diarrhea duration, onset timing, management strategies, and when to contact your prescriber.
Diarrhea occurred in 8.5% to 8.8% of people on Ozempic 0.5 mg or 1 mg vs 1.9% on placebo. See the label's kidney and pancreatitis warnings.
Ozempic (semaglutide) increases gallbladder disease risk through reduced motility, rapid weight loss, and cholesterol supersaturation. Learn the biology, risk factors, and management strategies.
A clinical severity grading rubric for gallbladder disease associated with Ozempic (semaglutide 0.5 to 2 mg), including mechanism, management, and when to escalate care.
Evidence-based guide to supplements that may reduce gallbladder disease risk while taking Ozempic (semaglutide 0.5 to 2 mg), including ursodiol, vitamin C, fiber, and omega-3s.
Learn the warning signs of gallbladder disease on Ozempic (semaglutide 0.5-2 mg), why it happens, how to manage it, and exactly when to seek emergency care.
Semaglutide (Ozempic) raises hypoglycemia risk when paired with insulin or sulfonylureas. Learn which GLP-1 and non-GLP-1 alternatives carry lower combination hypoglycemia risk, with trial data and dose-adjustment strategies.
Evidence-based diet protocols to reduce hypoglycemia risk when taking Ozempic with insulin or sulfonylureas. Includes meal timing, macronutrient targets, and glycemic management strategies.
The Ozempic label links added hypoglycemia risk to insulin or sulfonylureas. See trial rates of lows on Ozempic alone and with basal insulin.
A detailed clinical explanation of the biological mechanisms that cause nausea on Ozempic (semaglutide 0.5 to 2 mg), including delayed gastric emptying, area postrema activation, and vagal signaling, with evidence-based management strategies.
Evidence-based guide to supplements that may reduce nausea caused by Ozempic (semaglutide 0.5 to 2 mg), including ginger, vitamin B6, peppermint oil, and probiotics. Covers mechanism, dosing, and clinical trial data.
A clinical guide to pancreatitis risk with Ozempic (semaglutide), how the risk is understood, and which weight-loss or diabetes medications may be considered when pancreatitis has occurred or is a concern.
Persistent pancreatitis after Ozempic (semaglutide) use is rare but serious. Learn why it happens, how to manage it, when symptoms should resolve, and what options exist if they don't.
Evidence-ranked supplements and OTC agents for managing sulfur burps caused by Ozempic (semaglutide 0.5 to 2 mg), including ginger, peppermint oil, probiotics, bismuth subsalicylate, and digestive enzymes.
The injection-site reaction rate for TB-500 is unknown because FDA found no human study. See what FDA flags, plus oral gelatin and injected options.
FDA found no human studies of TB-500, no adverse-event reports and no toxicity studies, so its injection reactions are unknown.
Malaise is not a documented effect of TB-500. FDA found no human use of TB-500 and has flagged only a possible immune-reaction risk from injection.
Evidence-based severity grading rubric for mild malaise and flu-like symptoms associated with TB-500 (thymosin beta-4). Includes management strategies, duration expectations, and clinical decision points.
Persistent malaise or flu-like symptoms after TB-500 (thymosin beta-4) injections may signal more than a normal immune response. Learn timelines, red flags, and clinical steps when symptoms don't resolve.
Whether TB-500, a fragment of thymosin beta-4, raises cancer risk is unknown. FDA found no human studies, and the one cell study used the full protein.
TB-500 lacks long-term human safety data. Learn why this gap exists, how to manage uncertainty, and which evidence-backed alternatives carry stronger safety profiles.
TB-500 lacks long-term human safety data. Learn which warning signs require immediate medical attention, how to monitor yourself while using TB-500, and what the limited evidence tells us about risks.
A clinical severity grading rubric for vivid dreams associated with TB-500 (thymosin beta-4), including mechanism hypotheses, management strategies, and when to adjust your protocol.
No link between TB-500 and vivid dreams is established. Sleep supplement trials in other groups did not test dream vividness or TB-500.
Acne trials of zinc, nicotinamide, omega-3s and pantothenic acid, and what is not known for men taking testosterone cypionate.
Evidence-based alternatives to testosterone cypionate for patients who develop erythrocytosis or elevated hematocrit on TRT, including lower-dose protocols, transdermal testosterone, SERMs, and newer formulations.
Evidence-based review of supplements studied for erythrocytosis and elevated hematocrit during testosterone cypionate therapy, including naringin, IP6, fish oil, and curcumin.
What to do when fertility suppression from testosterone cypionate persists after stopping TRT. Covers recovery timelines, risk factors for prolonged azoospermia, hCG and clomiphene protocols, and when to see a reproductive urologist.
Testosterone cypionate suppresses LH, FSH, and spermatogenesis. Learn when fertility changes require medical attention, how to manage suppression, and what recovery looks like after discontinuation.
A clinical breakdown of why testosterone cypionate causes gynecomastia, covering aromatization, estrogen receptor signaling, and evidence-based management strategies.
Why testosterone cypionate accelerates male-pattern hair loss. A clinical breakdown of the DHT pathway, androgen receptor sensitivity, follicular miniaturization, and evidence-based management strategies.
Evidence-based dietary strategies to reduce DHT-driven hair loss during testosterone cypionate therapy, including specific nutrients, foods, and meal patterns supported by clinical research.
Persistent constipation is one of the most commonly reported gastrointestinal side effects of Wegovy (semaglutide 2.4 mg). Here is why it happens, how to tell ordinary adjustment from a problem that needs treatment, and a stepwise, evidence-based approach to managing it.
A explanation of the GLP-1 receptor mechanisms, gut motility changes, bile acid shifts, and microbiome alterations that cause diarrhea during Wegovy (semaglutide 2.4 mg) treatment.
Learn when diarrhea from Wegovy (semaglutide 2.4 mg) requires medical attention, why it happens, how long it lasts, and evidence-based strategies to manage this common GLP-1 side effect.
Evidence-based dietary strategies to reduce Wegovy (semaglutide 2.4 mg) injection site reactions, including anti-inflammatory foods, histamine-lowering protocols, and nutrient support for subcutaneous tissue healing.
Evidence-based guide to supplements that may help manage Wegovy (semaglutide 2.4 mg) injection site reactions, including quercetin, bromelain, vitamin D, and omega-3 fatty acids.
Learn which Wegovy (semaglutide 2.4 mg) injection site reactions are normal and which require medical attention. Includes management tips, timelines, and red-flag symptoms.
A clinical grading rubric for nausea severity on Wegovy (semaglutide 2.4 mg), with evidence-based management strategies, mechanism of action, and trial-derived incidence data.
Evidence-based guide to supplements that reduce nausea from Wegovy (semaglutide 2.4 mg), including ginger, vitamin B6, peppermint, and probiotics, with dosing, trial data, and clinical context.
Learn when sulfur burps on Wegovy require medical attention, why semaglutide causes them, and evidence-based strategies to reduce this GI side effect.
A clinical breakdown of the peripheral and central nervous system mechanisms behind vomiting on Wegovy (semaglutide 2.4 mg), plus evidence-based strategies to reduce it.
Evidence-based dietary strategies to reduce vomiting on Wegovy (semaglutide 2.4 mg), including meal timing, food choices, hydration tactics, and when to call your doctor.
Vomiting is one of the most common side effects of Wegovy. Learn when vomiting on semaglutide 2.4 mg is expected, when it needs a call to your doctor, and when it needs emergency care.
How formal constipation severity grading differs from a home symptom record during Zepbound treatment, with the current CTCAE definitions and evidence limits.
What psyllium, magnesium, probiotics and prunes have actually shown in constipation studies, and how that evidence applies to symptoms during Zepbound treatment.
Explore why Zepbound (tirzepatide) causes diarrhea, evidence-based management strategies, and alternative GLP-1 or non-GLP-1 weight-loss medications that may spare this side effect.
Diarrhea affected 19% to 23% of Zepbound users vs 8% on placebo. Diet evidence here comes from lactose, coffee and fiber studies.
Zepbound diarrhea occurred in 19% to 23% of patients in label trials vs 8% on placebo. See the fluid loss and abdominal pain warnings to watch for.
Learn when diarrhea from Zepbound (tirzepatide) requires medical attention, how to manage GI side effects at home, and which red-flag symptoms mean you should call your doctor immediately.
Explore why Zepbound causes hair loss, how to manage telogen effluvium on tirzepatide, and which weight-loss medications carry lower alopecia risk.
A clinical severity grading rubric for hair loss on Zepbound (tirzepatide), including telogen effluvium mechanisms, monitoring guidance, and evidence-based management strategies.